[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368471-105":59,"doc-detail-368471-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liquid-biopsy-in-diagnosis-and-monitoring-of-treatment-efficacy-in-patients-with-small-cell-lung-cancer-review","Liquid biopsy in diagnosis and monitoring of treatment efficacy in patients with small cell lung cancer - review","","Small-cell lung cancer (SCLC) remains highly lethal worldwide, with poor survival driven by rapid growth, frequent metastasis, and limited treatment options. While chemotherapy, radiotherapy, and newer immunotherapy strategies are used in clinical practice, responses are often inadequate and resistance can develop, highlighting the need for predictive biomarkers. Challenges in conventional tissue biopsy include insufficient or low-quality samples for biomarker analysis and limited ability to track tumor molecular changes during acquired resistance. Liquid biopsy offers a non-invasive alternative that enables measurement of biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). This review presents approaches for integrating liquid biopsy into SCLC diagnostics, including its role alongside imaging, molecular subtyping, and evaluation of predictive or prognostic biomarkers, with an overview of ongoing clinical trials collecting and assessing liquid biopsy in SCLC patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsy-in-diagnosis-and-monitoring-of-treatment-efficacy-in-patients-with-small-cell-lung-cancer-review/368471/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsy-in-diagnosis-and-monitoring-of-treatment-efficacy-in-patients-with-small-cell-lung-cancer-review/368471.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is liquid biopsy considered important in small-cell lung cancer (SCLC)?","Question",{"text":112,"@type":113},"Liquid biopsy is non-invasive, can be performed repeatedly with minimal risk, and allows measurement of tumor-derived biomarkers such as ctDNA and circulating tumor cells. It helps address limitations of tissue biopsy quality and availability in SCLC care.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinical problems in SCLC motivate the search for predictive biomarkers?",{"text":117,"@type":113},"SCLC patients often have poor responses to therapy and may develop resistance after initial effectiveness. The lack of appropriate predictive biomarkers for different treatment approaches is highlighted as a crucial problem.",{"name":119,"@type":110,"acceptedAnswer":120},"How does liquid biopsy support monitoring of treatment efficacy in SCLC?",{"text":121,"@type":113},"It enables biomarker assessment from liquid samples over time, which may facilitate tracking tumor molecular changes associated with acquired resistance. The review also discusses its potential use alongside imaging and in molecular subtyping.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368471,1790217592,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Molecular Biology Reports (2025) 52:455  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1033-025-10569-1  \nREVIEW  \nLiquid biopsy in diagnosis and monitoring of treatment efficacy inpatients with small cell lung cancer  \nNatalia Galant1 · Anna Grenda1 · Paweł Krawczyk1 · Mateusz Pięt2 · Janusz Milanowski1  \nReceived: 27 January 2025 / Accepted: 2 May 2025 / Published online: 13 May 2025 © The Author(s) 2025  \nAbstract  \nSmall-cell lung cancer (SCLC) remains one of the deadliest cancers worldwide. Patients’ survival remains poor due to its rapid growth, high metastatic rate and limited possibilities of treatment. For many years, SCLC management has been based mostly on chemo and radiotherapy. However, new therapeutic approaches have been proposed in the past few years, including immunotherapy, which is currently implemented in clinical practice. Unfortunately, in many cases, response to therapy, especially chemotherapy, remains poor, or the patient becomes resistant to initially effective treatment. Oneof the crucial problems during SCLC patient care is a lack of appropriate predictive biomarkers for various therapeutic approaches. Another critical issue is the scarcity of collected tissue during biopsy, which may be insufficient or of too poor quality for analysis. A liquid biopsy might be the key to solving both of those problems as it is collected in a non-invasive way and enables the measurement of various biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) . In this review, we discuss various approaches to potentially incorporating liquid biopsy into clinical application-as a companion to imaging during SCLC diagnostics, a new approach to molecular subtyping, and a material enabling predictive or prognostic biomarkers assessment. We also summarize ongoing clinical trials encompassing SCLC patients in which liquid biopsy is collected and examined.  \nKeywords Small-cell lung cancer · SCLC · Liquid biopsy · Next generation sequencing · CfDNA · CfRNA  \nIntroduction  \nSmall-cell lung cancer (SCLC) represents approximately 15% of lung cancer incidents worldwide [1] . Due to its rapid growth, high vascularity and wide ability to form metastases, it is often diagnosed at an extensive stage (ES-SCLC)[2, 3] . Therefore, SCLC is one of the deadliest cancers in the world, and the five-year survival rate is observed in only 7% of patients [1, 4] . SCLC is known as highly associated with tobacco exposure [5, 6], and still occurs more often in males than in females. However, this distinction is blurring [3] .  \nAs proposed therapies remain ineffective in a large subset of patients, a better understanding of sensitivity to treatment  \n􀀍 Natalia Galant [nataliagalant@umlub.pl](nataliagalant@umlub.pl)  \n1 Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland  \n2 Department of Virology and Immunology, Maria CurieSkłodowska University, Lublin, Poland  \nin the SCLC cohort is still needed [7–9] . The majority of SCLC cases are associated with TP53 (Tumor Protein 53) and RB1 (Retinoblastoma) mutations [2, 3, 10] . However, it is known that its molecular landscape is more complex. In recent years, further classification of SCLC has been proposed, including its division into four molecular subtypes: SCLC-A, SCLC-N, SCLC-P and SCLC-Y. Those subtypes are associated with overexpression of transcriptional factors: Achaete-Scute Family BHLH Transcription Factor 1 (ASCL1), Neuronal Differentiation 1 (NEUROD1), POU Class 2 Homeobox 3 (POU2F3) and Yes1 Associated Transcriptional Regulator (YAP1) [7, 11, 12] . To improve the effectiveness of implemented therapies, clinical trials analysing different therapeutical approaches, including divergent strategies in specific molecular subtypes, are currently underway [9, 11] .  \nHowever, immunotherapy with anti-PD-L1 antibodies (atezolizumab, durvalumab) in combination with chemotherapy is the most effective inpatients with ","cbCainXn3n6Qo4xp","https://ap.wps.com/l/cbCainXn3n6Qo4xp","pdf",1596002,14,"English","# Introduction\n## Liquid biopsy\n# Liquid biopsy in diagnosis and monitoring\n## Companion to imaging\n## Molecular subtyping\n## Predictive and prognostic biomarkers\n## Ongoing clinical trials","[{\"question\":\"Why is liquid biopsy considered important in small-cell lung cancer (SCLC)?\",\"answer\":\"Liquid biopsy is non-invasive, can be performed repeatedly with minimal risk, and allows measurement of tumor-derived biomarkers such as ctDNA and circulating tumor cells. It helps address limitations of tissue biopsy quality and availability in SCLC care.\"},{\"question\":\"What clinical problems in SCLC motivate the search for predictive biomarkers?\",\"answer\":\"SCLC patients often have poor responses to therapy and may develop resistance after initial effectiveness. The lack of appropriate predictive biomarkers for different treatment approaches is highlighted as a crucial problem.\"},{\"question\":\"How does liquid biopsy support monitoring of treatment efficacy in SCLC?\",\"answer\":\"It enables biomarker assessment from liquid samples over time, which may facilitate tracking tumor molecular changes associated with acquired resistance. The review also discusses its potential use alongside imaging and in molecular subtyping.\"}]","Liquid biopsy in diagnosis and monitoring of treatment efficacy in patients with small cell lung cancer - review | PDF",1790177126,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b13ce0de38fd93d63889e382937df2a.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6957d02b5cd961dcebf670410c6ddda.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaa90a5c5b4f56e19a0552cb2d5c687f.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/212d3e81e07628ea4a3541268cf57eeb.webp",980,1301]